ABSTRACT
The global in vitro diagnostics industry is predicted to grow rapidly in the coming years to reach a value of approximately US$ 52 billion by the end of 2013, with a 5% annual growth rate from 2011 to 2013 [1]. Among the various in vitro diagnostic constituents, point-of-care testing (POCT) constitutes the most lucrative share of the global market.
